Career & Filing History
Every role Jack A. Khattar has reported on a Form 4, reconstructed from the filings themselves. Reporting insiders must state their relationship to the issuer (officer title, director seat, or 10% ownership) on every filing.
Jack A. Khattar serves as President, CEO of SUPERNUS PHARMACEUTICALS, INC. (SUPN). Khattar has also held reporting roles at COGNITION THERAPEUTICS INC (CGTX) and scPharmaceuticals Inc. (SCPH). Khattar has reported 27 insider filings with the SEC since 2024. The most recent filing was in August 2026.
Every role Jack A. Khattar has reported on a Form 4, reconstructed from the filings themselves. Reporting insiders must state their relationship to the issuer (officer title, director seat, or 10% ownership) on every filing.
SUPERNUS PHARMACEUTICALS, INC. (SUPN)2 filingsCOGNITION THERAPEUTICS INC (CGTX)1 filingUpdated Aug 31, 2026
Jack A. Khattar is President, CEO, Director of SUPERNUS PHARMACEUTICALS, INC. (SUPN). 26 SEC Form 4 filings on record going back to 2024, most recently on 14 August 2026. Most recent open-market trade: sold $6K of SUPN on 16 March 2026. Lifetime open-market sales: $29.43M.
Every recent SEC Form 4 transaction Jack A. Khattar has reported, most recent first.
InsiderAlpha's records for Jack A. Khattar go back to 2024: 26 primary Form 4 filings, an average of 8.7 per year. 15 recorded transactions carry a Rule 10b5-1 flag, meaning they were pre-scheduled under a written trading plan rather than discretionary.
Insiders who reported open-market trades in the last 12 months at the companies Jack A. Khattar files at. Multiple unrelated insiders buying the same stock within a short window, cluster buying, has historically been one of the strongest Form 4 signals.
Other corporate insiders with significant SEC Form 4 track records on InsiderAlpha:
Jack A. Khattar is a corporate insider, tracked as President, CEO, Director of SUPERNUS PHARMACEUTICALS, INC. (SUPN). InsiderAlpha holds 26 primary Form 4 filings for them, the earliest from 2024, updated as new SEC EDGAR filings are processed.
3 primary Form 4 filings in the last 90 days, covering 2 companies.
Recorded transactions: 0 open-market purchases and 22 open-market sales ($29.43M) across all tracked filings.
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
A free account opens the full scored daily plan and every past day, a watchlist for any ticker, and 3 months of price history on every company page. No card.
Free plan available · Paid plans start with a 7-day free trial
$CGTX COGNITION THERAPEUTICS INC25.0K shares @ $0.00-